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In Brief
Hayatsu et al. report that an IPEXassociated Foxp3 mutation has expanded DNA recognition specificity and impairs tissue Treg cell fitness by repressing Batf. Their findings identify BATF as a critical regulator of tissue Treg cells and suggest that polymorphisms that impact Foxp3-DNA interactions may contribute to susceptibility to autoimmune disease.
SUMMARY
Foxp3 controls the development and function of regulatory T (Treg) cells, but it remains elusive how Foxp3 functions in vivo. Here, we established mouse models harboring three unique missense Foxp3 mutations that were identified in patients with the autoimmune disease IPEX. The I363V and R397W mutations were loss-of-function mutations, causing multi-organ inflammation by globally compromising Treg cell physiology. By contrast, the A384T mutation induced a distinctive tissue-restricted inflammation by specifically impairing the ability of Treg cells to compete with pathogenic T cells in certain nonlymphoid tissues. Mechanistically, repressed BATF expression contributed to these A384T effects. At the molecular level, the A384T mutation altered Foxp3 interactions with its specific target genes including Batf by broadening its DNA-binding specificity. Our findings identify BATF as a critical regulator of tissue Treg cells and suggest that sequence-specific perturbations of Foxp3-DNA interactions can influence specific facets of Treg cell physiology and the immunopathologies they regulate.
INTRODUCTION
Regulatory T (Treg) cells that express the X chromosomeencoded transcription factor (TF) Foxp3, one of four members of the P-subfamily of forkhead box TFs, establish and maintain immunological self-tolerance and homeostasis by restraining pathological immune responses including autoimmunity, inflammation, and allergy (Sakaguchi, 2004) . The importance of Foxp3 + Treg cells is highlighted by the finding that Foxp3 mutations lead to defective generation of functional Treg cells and thereby cause a devastating multi-organ autoimmune disease in scurfy mutant mice and in humans with the immune dysregulation, polyendocrinopathy, enteropathy, and X-lined (IPEX) syndrome (Bennett et al., 2001; Brunkow et al., 2001; Fontenot et al., 2003; Khattri et al., 2003; Wildin et al., 2001) . Furthermore, ectopic Foxp3 expression confers Treg cell-like phenotype and function on CD4 + conventional T (Tconv) cells (Fontenot et al., 2003; Hori et al., 2003) . These findings led to the notion that Foxp3 acts as a ''master regulator'' of Treg cells.
To determine the contribution of Foxp3 to Treg cell development and function, two groups have generated Foxp3 null mice in which transcriptional activity at the Foxp3 locus can be monitored by expression of a green fluorescence protein (GFP) reporter Lin et al., 2007) . Analysis of such Foxp3 null GFP + ''would-be'' Treg cells has revealed that full acquisition of Treg cell features including suppressor activity, repressed pro-inflammatory activity, and cellular fitness requires expression of a functional Foxp3 protein, although the characteristic Treg cell-like transcriptome can be partly induced in its absence. Furthermore, Foxp3 has been shown to bind to thousands of genomic sites (Marson et al., 2007; Samstein et al., 2012; Zheng et al., 2007) and interact with hundreds of partner proteins (Rudra et al., 2012) to activate or repress gene expression in Treg cells. Thus, Foxp3 serves as a highly connected ''hub,'' interacting with numerous targets and partners in the complex molecular network that orchestrates Treg cell development and function. However, because of the complexity of this network, the molecular mechanisms by which Foxp3 functions in Treg cells remain elusive. RPPFTYATLIRWAILEAPERQRTLNEIYHWFTRMFAYFRNHPATWKNAIRHNLSLHKCFVRVESEKGAVWTVDEFEFRKKR RPPFTYATLIRWAILEAPEKQRTLNEIYHWFTRMFAFFRNHPATWKNAIRHNLSLHKCFVRVESEKGAVWTVDELEFRKKR ******************* **************** ************************************* ****** Identification and functional analysis of Foxp3 alleles that affect only specific interactions with its transcriptional targets or partners would help dissect the complex processes integrated by Foxp3. Certain missense FOXP3 mutations identified in human IPEX may represent such examples. While IPEX is associated with both nonsense and missense FOXP3 mutations, the majority are missense mutations localized at the forkhead (FKH) DNA-binding domain (Bacchetta et al., 2016; Barzaghi et al., 2012) , which also mediates interaction with the nuclear factor of activated T cells (NFAT) family of TFs and formation of a domain-swapped dimer (Bandukwala et al., 2011; Wu et al., 2006) . Among the IPEX mutations in this domain, some impair dimerization, whereas some others including I363V, A384T, and R397W are predicted to disrupt DNA binding (Bandukwala et al., 2011; Stroud et al., 2006) . Analysis of the FOXP3-NFAT-DNA co-crystal structures revealed that the residues R397 and I363, highly conserved in FKH TFs, were at or near the interface with the DNA backbone. On the other hand, residue A384, conserved only in the P-subfamily members, lies within helix 3 (H3), the canonical DNA recognition helix that is docked into the major groove of DNA and provides amino acids that interact with the nucleobases of DNA ( Figure 1A ; Bandukwala et al., 2011; Stroud et al., 2006) . These results suggest that, while the R397W and I363V mutations impair the general DNA-binding activity of Foxp3, the A384T mutation may alter the sequence specificity of DNA binding (Wildin et al., 2001 ). This prediction prompted us to hypothesize that, unlike the I363V and R397W mutations, the A384T mutation may alter Foxp3 interactions with specific target genes and thereby interfere with a specific and important aspect of Treg cell physiology.
In this study, we tested our hypothesis by investigating how the A384T and other mutations impact on Treg cells and selftolerance through the generation of strains of mice carrying these mutant Foxp3 alleles. We found that I363V and R397W are hypomorphic and amorphic mutations, respectively, that disrupt Foxp3-DNA interactions and cause multi-organ inflammation by globally compromising Treg cell physiology. By contrast, the A384T mutation perturbed Foxp3 interactions with only some specific target genes by broadening its DNAbinding specificity, and induced a distinctive pattern of tissuerestricted inflammation by impairing Treg cell function in certain non-lymphoid tissues. Repressed expression of the AP-1 TF BATF by the A384T mutant contributed to the impaired function of such tissue Treg cells.
RESULTS
The A384T Mutation Perturbs Expression of a Subset of Foxp3-Dependent Genes As an initial approach to explore our hypothesis, we first asked whether the A384T mutation perturbs specific facets of Treg cell phenotype and function. For comparison, we also analyzed the I363V and R397W mutations. As an initial approach, we retrovirally transduced wild-type (WT) or mutant Foxp3 into mouse naive CD4 + T cells. These proteins were expressed at comparable levels ( Figure S1A ) and failed to induce endogenous Foxp3 transcription (not shown). R397W was fully, and I363V was partially, defective in the ability to increase the expression of CD25 and CTLA-4, whereas A384T did not show such defects ( Figure S1A ). Microarray analysis further revealed that R397W-transduced T cells were nearly identical to mock-transduced T cells, whereas A384T-transduced T cells were most similar to WT-transduced T cells ( Figure S1B ). The A384T mutation did, however, perturb expression of certain specific genes ( Figure 1C ). The ratio of hCD2 + cells to GFP + cells was reduced in the thymus and more markedly in the spleen of R397W and I363V heterozygous mice as compared to that in control mice ( Figure 1C ). Foxp3 and hCD2 expression levels were also reduced in these mutant hCD2 + T cells (hereafter designated as I363V and R397W Treg cells) ( Figure 1D ). These mutations therefore impair Treg cell development and maintenance. In A384T heterozygous mice, this ratio was reduced only in the spleen ( Figure 1C ) and Foxp3 See also Figure S1 . and hCD2 levels were unaffected in A384T Treg cells ( Figure 1D ), suggesting that this mutation selectively reduces competitive fitness of Treg cells in the periphery. In line with the results with transduced T cells ( Figure S1B ), microarray analysis revealed that A384T Treg cells were most similar to, albeit distinct from, WT Treg cells. By contrast, I363V and R397W Treg cells were more closely related to each other and to Foxp3
À Tconv cells ( Figure 1E ). Of note, whereas R397W-transduced T cells were nearly identical to mock-transduced T cells ( Figure S1B ), R397W Treg cells were distinct from, albeit closely related to, Tconv cells. This is consistent with the notion that the Treg cell transcriptome is also controlled by Foxp3-independent mechanisms Lin et al., 2007) , which operate in both WT and mutant Treg cells but not in transduced Tconv cells. Flow cytometric analysis confirmed reduced CD25 and CTLA-4 levels in I363V and R397W, but not in A384T, Treg cells ( Figure 1D (Smigiel et al., 2014) . In line with the preferential deficiency of A384T Treg cells in nonlymphoid tissues ( Figure 3A ), A384T emTreg cells, but not cTreg cells, showed reduced competitive fitness ( Figure 3B ). For both cTreg and emTreg cell subsets, the frequency of Ki67 + cells was lower in A384T Treg cells ( Figure 3C ). Because cTreg cells differentiate into emTreg cells as they undergo proliferation (Smigiel et al., 2014 ; data not shown), the A384T mutation appears to impair both differentiation and expansion of emTreg cells. In A384T hemizygous mice, the frequency of emTreg cells among total CD4 + T cells appeared normal in all tissues except the skin ( Figure 3D ), indicating that emTreg cells are able to accumulate in the presence of inflammation or in the absence of competition with WT Treg cells. However, because the frequency of emTconv cells was elevated in inflamed tissues (i.e., skin, lung, and colon) ( Figure 3D ), the balance between emTreg and emTconv cells was tilted toward the latter in those inflamed tissues, but not in the non-inflamed tissue, liver (Figure 3E) . Such an imbalance was also seen in the inflamed colon in the above transfer experiment ( Figure S3C ). Thus, A384T Treg cells are impaired in competing with emTconv cells at sites of inflammation. These results suggest that the defective in vivo regulatory function of A384T Treg cells stems from the impaired ability of emTreg cells to compete with pathogenic Th cells at sites of inflammation.
Selective Reduction of GATA3, ST2, and CCR4 Expression in A384T emTreg Cells Is Associated with Th2-Cell-and Th17-Cell-Deviated Tissue-Restricted Inflammation Why then do A384T mice show preferential dysregulation of Th2 and Th17 cell responses and little hepatic inflammation under homeostatic conditions? Recent studies have shown that emTreg cells consist of different subsets distinguished by expression of certain surface markers and TFs, particularly the TFs that direct Th cell subset differentiation (e.g., Tbet, GATA3, and RORgt), and that expression of these TFs in Treg cells may contribute to regulation of specific types of effector Th cells (Cretney et al., 2013; Josefowicz et al., 2012; Koch et al., 2009; Ohnmacht et al., 2015; Rudra et al., 2012; Sefik et (E) Frequency of hCD2 + cells in the indicated CD4 + T cell subsets (n = 5-7; mean ± SD).
See also Figure S3 .
respectively) as genes with significantly lower expression levels in A384T Treg cells (Table S1 ), a result confirmed by flow cytometric analysis ( Figure S4A ). ST2, the IL-33 receptor, is preferentially expressed by GATA3 hi emTreg cells and is required for their expansion and accumulation in inflamed tissues (Kolodin et al., 2015; Schiering et al., 2014; Vasanthakumar et al., 2015) but is also expressed in GATA3
hi Th2 cells and controls their pathogenicity (Endo et al., 2015) . In A384T hemizygous mice, the frequency of not only ST2 + but also GATA3 hi emTreg cells was Figures S4C and S4D ). However, other A384T emTreg cell subsets also showed a reduced competitive fitness in this setting ( Figure S4C ). We also noted that GATA3 hi and RORgt + emTconv cells were less abundant in the liver than in the lung or colon ( Figure 4B ). Thus, the liver is not a favorable environment for accumulation of Th2 and Th17 cells. The selective imbalance between GATA3 hi emTreg and emTconv cells therefore only marginally affects the overall balance between emTreg and emTconv cells in the liver.
In sum, A384T emTreg cells show selective reduction of GATA3, CCR4, and ST2 expression, and this phenotype is associated with the Th2-cell-and Th17-cell-deviated and tissuerestricted inflammation in A384T mice.
Reduced BATF Expression Contributes to the Defective Function of A384T Treg Cells
To identify the Foxp3 target gene(s) that could contribute to the A384T Treg cell phenotype, we examined two microarray datasets, one from WT-or A384T-transduced Tconv cells and the other from WT and A384T Treg cells. Among the differentially expressed genes between the WT and A384T groups (Tables S1  and S2 ), only a small fraction was common to the two datasets ( Figure 5A ), suggesting that this mutation alters gene expression in a cellular context-dependent manner. Because many of the differentially expressed genes may be indirect targets of Foxp3, we further performed Foxp3 chromatin immunoprecipitation followed by high-throughput sequencing (ChIP-seq) in WT and A384T Treg cells and identified 839 genomic sites, associated with 680 genes, that had significant differential Foxp3 binding between WT and A384T Treg cells (see below). Only two genes, Batf and Hdac5, were common to the three datasets (Figure 5A) . The decreased levels of Batf expression attracted our attention because TFs directing differentiation of effector Th cells contribute to the regulation by Treg cells of the corresponding Th cells (Cretney et al., 2013; Josefowicz et al., 2012) . Furthermore, BATF directs differentiation of certain Th cell subsets including Th2 and Th17 cells (Betz et al., 2010; Murphy et al., 2013; Schraml et al., 2009) . Flow cytometric and quantitative RT-PCR analyses confirmed reduced BATF expression both at the mRNA and protein levels in A384T-transduced T cells and in A384T Treg cells ( Figures 5B-5D and S5A-S5C). Moreover, BATF levels were increased in emTreg cells relative to cTreg cells and reduced in both subsets of A384T Treg cells compared to their WT counterparts ( Figure 5D ). We therefore hypothesized that the reduced BATF expression contributes to the A384T Treg cell phenotypes.
To address the functional relevance of reduced BATF expression, we first took loss-of-function approaches. We reasoned that if decreased BATF expression contributes to the A384T Figure S6B ). BATF-transduced, but not mock-transduced, A384T Treg cells prevented the development of colitis ( Figure 6F ) and accumulated more robustly than mock-transduced cells, particularly in the colon ( Figure 6G ), without increasing the numbers of total Treg cells ( Figure 6H ). Furthermore, when transferred into lymphopenic mice, BATF-transduced A384T Treg cells showed enhanced proliferation and accumulation of CCR7 lo emTreg cells that also display increased expression of CCR4 and GATA3, but not ST2 ( Figure 6I ). Thus, ectopic BATF expression rescued the impaired regulatory function and competitive ability of A384T Treg cells at a site of inflammation. Because BATF expression was not null in A384T Treg cells ( Figure S6C ), we retrovirally transduced Batf miRNA to silence BATF in WT Treg cells, which resulted in BATF levels comparable to those in A384T Treg cells ( Figures S6D and S6E ). We did not use Batf +/À Treg cells because their BATF levels were higher than in A384T Treg cells ( Figure S6C ). When Batf These results collectively suggest that reduced BATF expression accounts at least partly for the A384T Treg cell phenotypes.
A384T Represses BATF Expression by Acting as a Gain-of-Function Mutant Exhibiting Broadened DNA-Binding Specificity To address how the A384T mutation perturbs only a subset of Foxp3 target genes including Batf, we examined Foxp3 ChIPseq data. Among 6,817 consensus Foxp3-binding peaks called in either WT or A384T Treg cells, differential binding analysis identified 242 (3.62%) and 597 (8.76%) sites that had significantly more Foxp3 binding in WT or A384T Treg cells (designated as ''WT-specific'' or ''A384T-specific'' sites, respectively) (Figure 7A , Table S4 ). Motif analysis of the consensus Foxp3-binding sites revealed significant enrichment of not only the FKH motif but also the motifs of Foxp3 partners including the ETS, RUNX, SP1/KLF, AP-1, NF-kB, HIF-1a, and IRF motifs (data not shown). Differential motif enrichment analysis revealed that, whereas no known motifs were significantly enriched in the WT-specific sites relative to the remaining Foxp3-binding sites, motifs recognized by FKH TFs were significantly enriched in the A384T-specific sites ( Figure 7B ). Moreover, differential de novo motif searches revealed enrichment of sequences similar to the FKH motifs, RY-MAACA (Carlsson and Mahlapuu, 2002) in the A384T-specific sites relative to the remaining sites ( Figure 7C ). These results suggest that the A384T mutation alters the DNA-binding specificity of Foxp3 and enhances its binding to these FKH motifs.
To directly test this possibility, we performed electrophoretic mobility shift assays (EMSA) to assess the ability of WT and A384T Foxp3 to bind to DNA probes containing various FKH motif-like sequences. Both WT and A384T Foxp3 proteins were expressed robustly and bound to the canonical FKH motif, GTAAACA, whereas only A384T bound strongly to FKH variant (B) Naive Tconv cells were transduced with WT-or A384T-expressing or mock Thy1.1 RV. Contour plots show representative Thy1.1 and BATF expression profiles. Cells were grouped into ten fractions based on Thy1.1 expression levels, used as a proxy for Foxp3 expression levels, according to the gates shown in the histograms. BATF geometric MFI value in each fraction was normalized to that of Thy1.1 À cells (n = 3; mean ± SD).
(C) BATF expression in the indicated subsets of splenic CD4 + T cells from heterozygous female mice (n = 5; mean ± SD).
(D) BATF expression in the CCR7 hi and CCR7 lo subsets of Treg and Tconv cells from hemizygous male mice (n = 6; mean ± SD).
See also Figure S5 . sequences GTCAACA and GTACACA ( Figures 7D and S7A) . Moreover, A384T bound to RCAAACA more strongly than WT, whereas both A384T and WT bound to RAAAACA equivalently ( Figure S7B ). These results are in full agreement with the data shown in Figure 7C and demonstrate that A384T is a gain-offunction mutation that increases the DNA-binding affinity to certain FKH motif-like sequences. We also found that the DNA-binding activity of Foxp3 was eliminated completely by R397W and partially by I363V ( Figures 7D and S7C ), demonstrating that both mutations diminish the DNA-binding activity, but R397W is amorphic while I363V is hypomorphic.
Finally, we addressed how the altered DNA-binding specificity of A384T causes reduced Batf expression. ChIP-seq ( Figure 7E , Table S4 ) and ChIP-qPCR ( Figure S7D ) analyses revealed that A384T occupied the Batf promoter region more robustly than WT, suggesting that A384T dominantly represses Batf promoter activity. Examination of the Batf promoter identified five FKH motif-like sequences within the Foxp3 ChIP-seq peak region ( Figure 7F ), four of which (two GTCAACA and two ATACACA) were bound more strongly by A384T than by WT in EMSA (Figure 7D ). This suggests that the presence of those ectopic FKH sites likely accounts for the robust occupancy of the promoter by A384T. We then cloned a genomic fragment containing the Batf promoter with or without deletion of the five FKH sites into a retrovirus (RV)-based reporter vector ( Figure 7G ) and transduced naive CD4 + T cells with the reporter RV together with WT-or A384T-expressing RV. As shown in Figure 7H , A384T reduced the expression levels of GFP reporter more efficiently than WT in a dose-dependent and a FKH site-dependent manner. Of note, WT-transduced cells also showed reduced Batf promoter activity when compared to mock-transduced cells ( Figure 7H ), although WT failed to decrease BATF expression levels ( Figures 5B and S5A ). This suggests that Foxp3 also acts on other genomic region(s) that are not included in the reporter vector to counteract its repressive activity on the Batf promoter.
In sum, these results demonstrate that the A384T mutation broadens sequence specificity of DNA binding and thereby leads to repressed Batf promoter activity.
DISCUSSION
Foxp3 is a pivotal hub in the molecular network that orchestrates Treg cell development and function. Characterization of mutant Foxp3 alleles that perturb only specific interactions with its target genes should be instrumental in dissecting the complex operation of the network. In this study, we showed that the Foxp3 A384T allele represents one such example. This mutation perturbed Foxp3 binding to a small fraction of its target genes by broadening the sequence specificity of Foxp3-DNA interactions. Whereas the I363V and R397W loss-of-function mutations caused multi-organ inflammation by compromising overall Treg cell physiology, the A384T mutation induced a distinctive tissue-restricted autoimmune phenotype by specifically impairing the ability of Treg cells to compete with pathogenic Tconv cells in certain tissues. Furthermore, our results demonstrated that the defective function of A384T Treg cells can be ascribed at least partly to direct repression by A384T of BATF expression.
Our results demonstrate that A384T acts as a gain-of-function mutation that increases the affinity to certain FKH motif-like sequences. Notably, this Ala residue is conserved only in Foxpsubfamily members, whereas the corresponding residue is Ser (or Thr) in all the other FKH TFs, which is biochemically more similar to the mutant residue Thr. Importantly, this Ser residue of FOXO1 and FOXK1a interacts with a nucleobase inside FKH motif sequences (Brent et al., 2008; Tsai et al., 2006) . Thus, this Ala to Thr substitution increases the affinity for certain FKH motif-like sequences, probably by providing an additional interface with those sequences. How then does the altered DNAbinding specificity perturb expression of specific Foxp3 target genes such as Batf? Our results suggest that Batf repression by A384T results from its preferential binding to the ectopic Thy1.1
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Thy1.1 fractions (legend on next page) FKH sites in the promoter. It remains to be investigated, however, whether the mode of repression is direct through competition with activating TFs or indirect through increased recruitment of repressive Foxp3 partners (Rudra et al., 2012) to the Batf promoter.
It is unlikely that the A384T mutation directly disrupts proteinprotein interactions between Foxp3 and its specific partner(s). First, this Ala residue, localized at the major-groove-occupying helix, would not be accessible to partners when this helix is docked to DNA. Second, this mutant protein would retain the ability to interact with many partners that bind outside the FKH domain and with NFAT, the only known FKH-interacting partner, because this residue is not at the interface and because defective Foxp3-NFAT interactions should lead to de-repression of IL-2 production and failure to increase CD25 and CTLA4 expression levels , phenotypes that were not seen in A384T Treg cells. Lastly, our ChIP-seq analysis revealed no relative enrichment of TF recognition motifs in the WT-specific Foxp3-binding sites. If this mutation disrupted interactions with any partners, their motifs should be significantly enriched in those sites because they were recruited to WT binding sites more efficiently than to A384T binding sites. This finding therefore suggests that the A384T mutation does not impair Foxp3 interactions with TFs with known motifs.
The A384T mutation selectively impaired in vivo regulatory function of Treg cells and caused tissue-restricted and Th2-cell-and Th17-cell-deviated inflammation under homeostatic conditions. Our results suggest that the defective in vivo regulatory function of A384T Treg cells stems from their impaired ability to compete with Tconv cells at the sites of inflammation, because the balance between emTreg cells and emTconv cells was tilted in favor of the latter only in the inflammatory tissues in A384T mice. Furthermore, this imbalance was restricted to the subsets expressing GATA3, ST2, and/or CCR4, which are expressed preferentially by Th2 and/or Th17 cells and are also required for Treg cells to migrate to certain non-lymphoid tissues (i.e., skin and lung, but not liver) (CCR4) (Sather et al., 2007) or to accumulate in certain environments (GATA3 and ST2) (Kolodin et al., 2015; Schiering et al., 2014; Vasanthakumar et al., 2015; Wang et al., 2011; Wohlfert et al., 2011) . The reduced expression of these molecules in A384T emTreg cells would therefore result in a relative Treg cell insufficiency, due to reduced migration and accumulation in the tissue microenvironments in which Th2 and Th17 cells are selectively recruited, undergo clonal expansion, and exert effector functions. This impaired adaptation of emTreg cells to Th2 and Th17 cell environments may also explain the negligible hepatic inflammation in A384T mice. Because the liver is not a Th2-cell-or Th17-cell-dominant environment, the selective dysregulation of Th2 and Th17 cell responses should cause relatively minor inflammation at this site as compared to the other inflamed tissues.
Our results suggest that Batf repression by A384T contributes to the defective function and fitness of Treg cells in these mutant mice. Because other A384T-perturbed target genes may also contribute and because our current approaches relied on retroviral transduction and adoptive transfer into lymphopenic mice, future studies should address to what extent repressed BATF expression accounts for the A384T Treg cell phenotype in intact lymphoreplete animals. In addition, it also remains to be elucidated whether Batf represents an important target of WT Foxp3. Nevertheless, our findings have revealed BATF to be a critical regulator of Treg cells in non-lymphoid tissues. Although previous studies have suggested that BATF is required for Treg cells to prevent colitis (Wang et al., 2013) and to accumulate in visceral adipose tissues (Vasanthakumar et al., 2015) by regulating gut homing molecules and ST2, respectively, our results indicate that its function is more fundamental in that it coordinates the differentiation and accumulation of various emTreg cell subsets. In line with this notion, previous studies have demonstrated that BATF plays an essential role in the differentiation and function of various effector T cell subsets by regulating expression of key TFs, cytokines, cytokine receptors, and chemokine receptors (Betz et al., 2010; Ise et al., 2011; Kurachi et al., 2014; Murphy et al., 2013; Schraml et al., 2009) . Future studies will reveal the in vivo function of BATF in Treg cells and the detailed molecular mechanisms by which it orchestrates the differentiation and function of emTreg cells.
Our findings in the mouse models of IPEX have important implications in understanding its pathogenesis in humans. Although IPEX is generally a fatal autoimmune disease affecting multiple tissues, its clinical manifestations are heterogeneous with respect to the severity and target tissue spectrum (Bacchetta et al., 2016; Barzaghi et al., 2012) . Our results demonstrate that the nature of the Foxp3 mutations contributes to See also Figure S7 .
this heterogeneity. In line with our findings, previous studies have reported that patients carrying the R397W mutation show severe symptoms, whereas patients carrying the A384T mutation exhibit milder ones (Bacchetta et al., 2016) . Nevertheless, patients with the A384T mutation exhibit drastically variable phenotypes in that some survived more than 10 years while others died as infants (Bacchetta et al., 2016; Barzaghi et al., 2012) . This indicates that not only the Foxp3 genotype but also environmental factors and other genetic variations are at the root of the interindividual variability. Indeed, our finding that the disease phenotypes of A384T mice can be different in homeostatic versus perturbed conditions suggest a role of environmental factors. In addition, genetic variations could also contribute because they may change FKH motif-like sequences, leading to gain or loss of transcriptional regulation by A384T and consequently to the inter-individual variability of Treg cells and clinical phenotypes. This possible contribution of genetic variations also suggests inter-species variability: the impact of the A384T mutation on Treg cell and clinical phenotypes might be different between humans and mice. Future studies should address to what extent the phenotypes of A384T mice are recapitulated in human patients.
In conclusion, the findings in this study suggest that sequence-specific perturbations of Foxp3-DNA interactions can impinge on specific facets of Treg cell physiology and precipitate distinctive immunopathologies. This notion may have implications in elucidating the pathogenesis of polygenic autoimmune, inflammatory, or allergic diseases as well. Because autoimmune disease-susceptible single nucleotide polymorphisms are often associated with enhancers that are preferentially active in Treg cells (Arvey et al., 2015; Trynka et al., 2013) , many of which are bound by Foxp3 , it will be important to address whether those variations result in loss or gain of Foxp3-dependent regulation at key target gene loci. Moreover, our analysis of an IPEX-associated missense Foxp3 mutation has identified BATF as a critical regulator of Treg cell function. Thus, further investigations of such mutant alleles will uncover functionally important Foxp3 target genes, which may serve as new targets for therapeutic manipulation of Treg cells in the context of autoimmunity, inflammation, allergy, and cancer.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: Cell Isolation Single-cell suspensions from thymus, peripheral (cervical, axillar, brachial, inguinal) LN, mesenteric LN, spleen, and Peyer's patch were obtained by gently forcing the tissues through a nylon mesh grid in Hanks's balanced salt solution (HBSS, Sigma) containing 2% FBS. Splenic erythrocytes were eliminated with ACK lysis buffer. Peyer's patches were incubated in HBSS containing 10% FBS, 15 mM HEPES and 5 mM EDTA for 20 min at 37 C with constant stirring to remove epithelial cells before the mechanical dissociation. Leukocytes from non-lymphoid tissues were isolated as follows. Lung was perfused with PBS, cut into small pieces and incubated for 80 min at 37 C with occasional vortexing in PBS containing 2% FBS, 100 U/ml collagenase type 1 (Worthington) and 100 mg/ml DNase I (Roche). Liver was perfused, homogenized using a steel mesh grid, and digested in PBS containing 100 U/ml collagenase type 1 and 100 mg/ml DNase I for 45 min. The resulting lung and liver suspension was passed through a 70 um cell strainer, treated with ACK lysis buffer, resuspended in 44% Percoll (GE Healthcare Life Sciences) layered on 56% Percoll, and centrifuged at 1,000 x g for 20 min. Leukocytes were recovered from the interface. To isolate colonic lamina propria leukocytes, large intestine was cut longitudinally and then laterally into 1-cm pieces, washed thoroughly in PBS, and incubated twice with constant stirring for 20 min at 37 C in HBSS containing 10 mM HEPES and 5 mM EDTA to remove epithelial cells. The remaining tissues were cut into small pieces, digested twice with constant stirring for 30 min at 37 C in RPMI-1640 containing 4% FBS, 200 U/ml collagenase type 1 and 100 mg/ml DNase I, vortexed and passed through a 70 um cell strainer. Leukocytes were isolated on a 40/80% Percoll density gradient (1,000 x g for 20 min). To obtain skin leukocytes, ear was excised and separated into the ventral and dorsal sheets, incubated in RPMI-1640 containing 4% FBS, 320 U/ml collagenase type 1 and 100 mg/ml DNase I for 2 hr at 37 C and 5% CO 2 , homogenized using a nylon mesh grid, and passed through a 70 um cell strainer. To enumerate the skin leukocytes, an aliquot of the resulting suspension was mixed with 1x10 6 Ly5.1 (CD45.1) spleen cells, stained with anti-CD45.1 and anti-CD45.2 antibodies, and analyzed on a flow cytometer. The number of skin CD45.2 + leukocytes was calculated according to the CD45.2 to CD45.1 ratio.
Plasmids Mouse Foxp3 cDNA was described previously (Hori et al., 2003) . The I363V, A384T, and R397W mutants were generated using QuickChange Site-Directed Mutagenesis Kit (Stratagene) and cloned into the MSCV-IRES-GFP (MIGR1) or -Thy1.1 RV vectors. For EMSA, cDNA encoding mouse Foxp3 lacking the first 181 amino acids (Foxp3DN) with or without the missense mutations were PCR amplified and cloned into the pTNT vector (Promega). Mouse BATF cDNA was generated by DNA synthesis and cloned into the pMCs-IRES-GFP or MSCV-IRES-Thy1.1 RV vectors. A BLOCK-iT Pol II miR RNAi Expression Vector Kit (Invitrogen) was used for Batf knockdown. The target sequence of Batf miRNA, designed using the BLOCK-iTÔ RNAi Designer (Invitrogen), was 5 0 -AGTA CTTGAGCTCCTCGGTGA-3 0 . The dsDNA encoding the Batf miRNA was cloned into the pcDNA6.2-GW/EmGFP plasmid (Invitrogen). The pcDNA6.2-GW/EmGFP-miR-neg control plasmid (Invitrogen) was used as a negative control. The entire emGFP-miRNA cassette was PCR amplified and cloned into the pMCs RV vector. For Batf promoter reporter assays, a 3.4 kb fragment of the Batf gene (À809 to +2,574) was PCR amplified and cloned in-frame into the hCD4-pA-GFP RV vector (Zhu et al., 2001 ). The D5xFKH mutant promoter was generated using a PCR-based site-directed mutagenesis method.
In Vitro T Cell Activation and Retroviral Transduction T cells were cultured in RPMI-1640 (GIBCO) supplemented with 10% FBS (Hyclone), 10 mM HEPES (Sigma-Aldrich), 1 mM sodium pyruvate (Sigma-Aldrich), 50 mM 2-ME (GIBCO), 100 U/ml penicillin (Sigma-Aldrich), 100 mg/ml streptomycin (Sigma-Aldrich). The Plat-E packaging cells (Morita et al., 2000) were cultured in DMEM, high glucose (Sigma) supplemented with 10% FBS and 10 mM HEPES, and transfected with retroviral vectors using FuGENE 6 Transfection Reagent (Promega). Viral supernatants were collected 48 hr later. For retroviral transduction of naive CD4 + T cells, sorted cells (1.5x10 6 cells/well) were activated with 0.5 mg/ml anti-CD3ε mAb (145-2C11) in the presence of 10 ng/ml rmIL-2 (R&D) and Thy1.2 + cell-depleted (or Cd3e
) and g-irradiated (20 Gy) syngeneic spleen cells as APCs (6x10 6 cells/well) in 24-well plates (2.0 ml/well). Cells were transduced 24 hr later using an equal volume of retroviral supernatant and 6 mg/ml polybrene (Sigma-Aldrich), and centrifuged at 1,580 x g for 60 min at 32 C. Cells were expanded and maintained in medium supplemented with 10 ng/ml rmIL-2, and analyzed on day 6 or 7 after activation. For retroviral transduction of Treg cells, sorted cells (1x10 6 /ml) were stimulated with CD3 and CD28 mAb-coated beads (Dynal) (1x10 6 /ml) in the presence of 10 ng/ml rmIL-2 in 48-well plates (0.8-1 ml/well), transduced after 40-42 hr, then expanded and maintained as above. Cells were harvested on day 4 for adoptive transfer experiments. analyzed by flow cytometry. To assess cytokine production, cells were stimulated for 4 hr at 37 C with 50 ng/ml PMA and 500 ng/ml ionomycin in the presence of GolgiPlug (BD Biosciences) before intracellular staining.
Microarray Analysis
Total RNA was isolated from sorted cells with Isogen reagent (Nippon Gene) and an RNeasy Mini Kit (QIAGEN), labeled with GeneChip One-Cycle (for retrovirally transduced Tconv cells) or Two-Cycle Target Labeling and Control Reagents (for Foxp3 mutant Treg cells) or 3 0 IVT Express Kit (for Batf À/À Treg cells) (Affymetrix), and hybridized to Mouse Genome 430 2.0 Arrays (Affymetrix). All cell populations analyzed were generated in duplicates or triplicates. GeneSpring GX software (version 13.0) (Agilent) and the R stats and amap packages were used for hierarchical clustering analysis. After raw data were normalized with the RMA algorithm, a one-way ANOVA with Benjamini-Hochberg multiple-testing correction was performed to identify probes that were differentially expressed among conditions. Probes were considered differentially expressed when they had corrected p-values of < 0.05. Hierarchical clustering analysis was performed on normalized expression values of the differentially expressed probes using the Euclidean metric and the Ward's linkage rule (using ''euclidean'' method in Dist function and ''ward.D2'' method in hclust function). The clustering results were visualized using the R ggplot2 and ggdendro packages.
Differential gene expression analysis was performed using the R Bioconductor package limma (Ritchie et al., 2015) . To identify genes differentially expressed between two conditions, a Bayes moderated t test was performed. To identify genes over-or under-represented in A384T Treg cells relative to WT Treg cells, a moderated one-way ANOVA was performed to compare A384T Treg cells with three types of WT Treg cells (i.e., GFP + Treg cells from Foxp3 A384T:hCD2/WT:GFP mice, hCD2 + Treg and GFP + Treg cells from Foxp3 WT:hCD2/WT:GFP mice). Genes were considered differentially expressed when they had p-values of < 0.01 and log2 foldchanges of > 0.5 or < À0.5 (for ANOVA, at least in one comparison).
Quantitative RT-PCR Total RNA from sorted cells was isolated using Isogen (Nippon Gene) and converted to cDNA using a SuperScript VILO cDNA Synthesis Kit or SuperScript III First-Strand Synthesis System (Invitrogen). Real-time PCR was performed with a Light Cycler 480 instrument (Roche) using KAPA PROBE FAST qPCR Kit (Kapa Biosystems) and Universal ProbeLibrary assays (Roche). Expression levels of Batf relative to Hprt were determined by the comparative C T (2 -DDCt ) method. Primer sequences and probe IDs can be found in Table S5 and the Key Resource Table, respectively.
Foxp3 ChIP-seq and ChIP-qPCR For Foxp3 ChIP experiments, polyclonal anti-mouse Foxp3 antibodies were raised by immunizing rabbits with E. coli-expressed fulllength recombinant mouse Foxp3 proteins and were affinity-purified using Foxp3-conjugated HiTrap NHS-activated HP columns (GE Healthcare Life Sciences). ChIP experiments were carried out as described previously (Kitoh et al., 2009 ) with some modifications. MACS-sorted hCD2 + WT and A384T Treg cells (approx. 1 x10 7 cells per reaction, prepared in triplicates) were fixed for 30 min at room temperature with 1% formaldehyde, washed with PBS, and stored at À80 C. Cells were resuspended in lysis buffers and sonicated for solubilization and shearing of crosslinked DNA. The cell extract was incubated overnight at 4 C with 4 mg of the anti-Foxp3 antibodies (or normal rabbit IgG [Cell Signaling Technology] for ChIP-qPCR) and then with Dynabeads protein G (Dynal). Bound complexes were washed and eluted from the magnetic beads by heating at 65 C with occasional vortexing and crosslinking was reversed by overnight incubation at 65 C. The immunoprecipitated DNA and whole-cell extract input DNA (for ChIP-seq) were treated with RNase A and proteinase K, purified using MinElute PCR Purification Kit (QIAGEN), and subjected to preparation of ChIP-seq libraries or ChIP-qPCR assays. ChIP-seq libraries were prepared using NEBNext ChIP-Seq Library Prep Master Mix Set for Illumina (New England Biolabs) according to the manufacturer's instructions, and were sequenced with single-end 50-bp reads on an Illumina HiSeq 1500. For ChIP-qPCR assays, occupancy of Foxp3 on the genes of interest was measured using a LightCycler 480 instrument (Roche), THUNDERBIRD SYBR qPCR mix (Toyobo). Primer sequences can be found in Table S5 .
Analysis of ChIP-seq Data DNA sequence reads were aligned to the mouse reference genome (UCSC mm9) using the Bowtie 2 software (Langmead and Salzberg, 2012) . Foxp3 ChIP-seq peaks were called with Model-based Analysis for ChIP-Seq (MACS (2.1.0)) (Zhang et al., 2008) using input chromatin as control and FDR q-value of < 10 À10 . Identification of consensus Foxp3 binding sites and differential binding analysis was performed with the R Bioconductor package DiffBind (version 1.12.2) (Ross-Innes et al., 2012). The Foxp3 ChIP-seq peaks that were called in at least two of the triplicate samples of the WT or A384T Treg cell sample group were considered as consensus Foxp3 binding sites. Among them, differentially bound sites were identified when they had FDR q-values of < 0.05. Motif analysis was performed with the MEME-ChIP program (Machanick and Bailey, 2011) . Annotation of the Foxp3 binding sites was done with the R Bioconductor package ChIPpeakAnno (Zhu et al., 2010) .
EMSA and Western Blot
Because DNA-binding activity of Foxp3 cannot be detected in EMSA unless its N-terminal region is deleted (Koh et al., 2009 ), we synthesized WT or mutant Foxp3 lacking the first 181 amino acids (Foxp3DN) or fire fly luciferase in vitro using the TNT Quick Coupled Transcription/Translation System (Promega). The nucleotide sequences of EMSA probes (63-bp) consisted of the M13(À20) sequence (5 0 -GTAAAACGACGGCCAGT-3 0 ), followed by CAAGNNNNNNNAGACAACNNNNNNNA and by the SP6 promoter sequence (5 0 -TTCTATAGTGTCACCTAAAT-3 0 ). The underlined 7 nucleotides, putative Foxp3 binding sites, were: RNAAACA, GTCAACA, GTACACA, or ATACACA. The EMSA probes were generated by PCR using a single-stranded synthetic oligonucleotide with the above sequence as a template, a 5 0 -biotinylated M13(À20) primer and a SP6 primer, and purified on agarose gels. Binding reactions were performed at room temperature for 30 min using 0.7 ml of in vitro-translated proteins and 0.5 ng of biotinylated dsDNA probes in 7 ml, in the presence of 10 mM HEPES (pH 7.0), 100 mM NaCl, 2.5 mM DTT, 0.5 mM EDTA, 10% glycerol, and 25 ng sonicated salmon sperm DNA (BioDynamics Laboratory). DNA:protein complexes were separated from free probe by electrophoresis in a 7.5% SuperSep ACE polyacrylamide gel (Wako Pure Chemical) and transferred to HybondN+ nylon membranes (Amersham). The biotinylated probes were revealed with LightShift Chemiluminescent EMSA Kit (Thermo Fisher Scientific).
To evaluate expression of WT or mutant Foxp3DN proteins, equal volumes of in vitro-translated proteins were subjected to SDS-PAGE and transferred to PVDF membranes (Whatman). Immunoblots were performed using polyclonal rabbit IgG raised against a synthetic peptide corresponding to residues 408-424 (near the C terminus) of mouse Foxp3 conjugated with thyroglobulin, diluted in TBS containing 0.2% Tween-20 and 5% Blocking One (Nacalai Tesque). Primary antibodies were revealed with HRP-conjugated TrueBlot anti-rabbit IgG (Rockland), followed by detection with Chemi-Lumi One (Nacalai Tesque).
Reporter Assay Naive CD4 + T cells were co-transduced with a 1:1 mixture of MSCV-IRES-Thy1.1 and hCD4-pA-GFP RV supernatants as described above. On day 6 after activation, cells were stained for mouse CD4, human CD4 and Thy1.1 and analyzed on a flow cytometer. For analysis, we used integrated MFI, which combines the metrics of frequency of GFP + cells and GFP MFI as a measure of total functional response (Shooshtari et al., 2010) .
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis was performed using Prism 6 (GraphPad Software). Statistical significance was evaluated by Student's t test or one-way ANOVA with the Dunnett's multiple comparisons test unless otherwise stated. Differences with p values % 0.05 were considered significant. NS, not significant; *p % 0.05; **p % 0.01; ***p % 0.001; ****p % 0.0001. n represents number of biological replicates.
DATA AND SOFTWARE AVAILABILITY
Microarray and ChIP-seq data are available at the NCBI GEO under accession number GSE89744.
